Despite decades of tireless advocacy to improve awareness, we recognized that the risk of change would be worth the reward. More information about the name change and access to resources on PMOS in multiple languages is available on the Monash Center for Health Research and Implementation website.
WADA status BPC-157 BPC-157 has no approval from any governmental regulatory health authority for human therapeutic use, and as such falls under WADA category S0 (Non-Approved Substances), prohibited at all times (ref
NNC 26-0161 was the development designation used during Novo Nordisk pharmaceutical work
By helping to neutralise free radicals and reduce cellular oxidative stress, it may support skin elasticity and promote a brighter, more even complexion over time
Succinylcholine is a depolarizing neuromuscular blocker that produces a Phase I block via persistent activation of post-synaptic nicotinic receptors, causing depolarization, transient fasciculations, sodium channel inactivation, and flaccid paralysis without fade
You can get back to your life and return to your normal activities immediately after your treatment
